Sees FY25 gross margin 73%-75%. Sees FY25 operating expenses $92M-$95M. The company said, “NeuroPace (NPCE) continues to expect revenue growth to be primarily driven by increasing sales of its RNS System, supported by higher sales of DIXI Medical stereo EEG products.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NPCE:
Questions or Comments about the article? Write to editor@tipranks.com